These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 28160245

  • 1. Lipoprotein(a)-hyperlipoproteinemia as cause of chronic spinal cord ischemia resulting in progressive myelopathy - successful treatment with lipoprotein apheresis.
    Heigl F, Hettich R, Mauch E, Klingel R, Fassbender C.
    Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):50-54. PubMed ID: 28160245
    [Abstract] [Full Text] [Related]

  • 2. Lipoprotein apheresis for Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease--Additional particular aspects of the Pro(a)LiFe multicenter trial.
    Klingel R, Heibges A, Fassbender C.
    Atheroscler Suppl; 2015 May; 18():35-40. PubMed ID: 25936302
    [Abstract] [Full Text] [Related]

  • 3. Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines.
    Klingel R, Heibges A, Fassbender C, Pro(a)LiFe-Study Group.
    Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):38-43. PubMed ID: 28185214
    [Abstract] [Full Text] [Related]

  • 4. Lipoprotein apheresis in patients with peripheral artery disease and lipoprotein(a)-hyperlipoproteinemia: 2-year follow-up of a prospective single center study.
    Poller WC, Berger A, Dreger H, Morgera S, Enke-Melzer K.
    Atheroscler Suppl; 2017 Nov; 30():174-179. PubMed ID: 29096834
    [Abstract] [Full Text] [Related]

  • 5. Lipoprotein apheresis in patients with peripheral artery disease and hyperlipoproteinemia(a).
    Poller WC, Dreger H, Morgera S, Berger A, Flessenkämper I, Enke-Melzer K.
    Atheroscler Suppl; 2015 May; 18():187-93. PubMed ID: 25936325
    [Abstract] [Full Text] [Related]

  • 6. Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany.
    Heigl F, Hettich R, Lotz N, Reeg H, Pflederer T, Osterkorn D, Osterkorn K, Klingel R.
    Atheroscler Suppl; 2015 May; 18():154-62. PubMed ID: 25936320
    [Abstract] [Full Text] [Related]

  • 7. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study.
    Leebmann J, Roeseler E, Julius U, Heigl F, Spitthoever R, Heutling D, Breitenberger P, Maerz W, Lehmacher W, Heibges A, Klingel R, Pro(a)LiFe Study Group*.
    Circulation; 2013 Dec 17; 128(24):2567-76. PubMed ID: 24056686
    [Abstract] [Full Text] [Related]

  • 8. Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease.
    Heigl F, Hettich R, Lotz N, Reeg H, Pflederer T, Osterkorn D, Osterkorn K, Klingel R.
    Clin Res Cardiol Suppl; 2015 Apr 17; 10(Suppl 1):8-13. PubMed ID: 25672934
    [Abstract] [Full Text] [Related]

  • 9. Effects of Lipoprotein apheresis on the Lipoprotein(a) levels in the long run.
    Groß E, Hohenstein B, Julius U.
    Atheroscler Suppl; 2015 May 17; 18():226-32. PubMed ID: 25936330
    [Abstract] [Full Text] [Related]

  • 10. Rationale and design of MultiSELECt: A European Multicenter Study on the Effect of Lipoprotein(a) Elimination by lipoprotein apheresis on Cardiovascular outcomes.
    Hohenstein B, Julius U, Lansberg P, Jaeger B, Mellwig KP, Weiss N, Graehlert X, Roeder I, Ramlow W.
    Atheroscler Suppl; 2017 Nov 17; 30():180-186. PubMed ID: 29096835
    [Abstract] [Full Text] [Related]

  • 11. Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization.
    Roeseler E, Julius U, Heigl F, Spitthoever R, Heutling D, Breitenberger P, Leebmann J, Lehmacher W, Kamstrup PR, Nordestgaard BG, Maerz W, Noureen A, Schmidt K, Kronenberg F, Heibges A, Klingel R, Pro(a)LiFe-Study Group.
    Arterioscler Thromb Vasc Biol; 2016 Sep 17; 36(9):2019-27. PubMed ID: 27417585
    [Abstract] [Full Text] [Related]

  • 12. Lipoprotein apheresis results in plaque stabilization and prevention of cardiovascular events: comments on the prospective Pro(a)LiFe study.
    Klingel R, Heibges A, Fassbender C.
    Clin Res Cardiol Suppl; 2015 Apr 17; 10(Suppl 1):46-50. PubMed ID: 25644612
    [Abstract] [Full Text] [Related]

  • 13. The impact of lipoprotein apheresis in patients with refractory angina and raised lipoprotein(a): Objectives and methods of a randomised controlled trial.
    Khan TZ, Pottle A, Pennell DJ, Barbir MS.
    Atheroscler Suppl; 2015 May 17; 18():103-8. PubMed ID: 25936312
    [Abstract] [Full Text] [Related]

  • 14. Specific Lipoprotein(a) apheresis attenuates progression of carotid intima-media thickness in coronary heart disease patients with high lipoprotein(a) levels.
    Ezhov MV, Safarova MS, Afanasieva OI, Pogorelova OA, Tripoten MI, Adamova IY, Konovalov GA, Balakhonova TV, Pokrovsky SN.
    Atheroscler Suppl; 2015 May 17; 18():163-9. PubMed ID: 25936321
    [Abstract] [Full Text] [Related]

  • 15. The German Lipoprotein Apheresis Registry (GLAR) - almost 5 years on.
    Schettler VJJ, Neumann CL, Peter C, Zimmermann T, Julius U, Roeseler E, Heigl F, Grützmacher P, Blume H, Vogt A, Scientific Board of GLAR for the German Apheresis Working Group.
    Clin Res Cardiol Suppl; 2017 Mar 17; 12(Suppl 1):44-49. PubMed ID: 28233268
    [Abstract] [Full Text] [Related]

  • 16. Actual situation of lipoprotein apheresis in patients with elevated lipoprotein(a) levels.
    Julius U, Tselmin S, Schatz U, Fischer S, Birkenfeld AL, Bornstein SR.
    Atheroscler Suppl; 2019 Dec 17; 40():1-7. PubMed ID: 31818437
    [Abstract] [Full Text] [Related]

  • 17. Kinetics of Lipoprotein(a) in patients undergoing weekly lipoprotein apheresis for Lp(a) hyperlipoproteinemia.
    Tselmin S, Müller G, Schatz U, Julius U, Bornstein SR, Hohenstein B.
    Atheroscler Suppl; 2017 Nov 17; 30():209-216. PubMed ID: 29096840
    [Abstract] [Full Text] [Related]

  • 18. Association of lipoprotein(a) level with short- and long-term outcomes after CABG: The role of lipoprotein apheresis.
    Ezhov MV, Afanasieva OI, Il'ina LN, Safarova MS, Adamova IY, Matchin YG, Konovalov GA, Akchurin RS, Pokrovsky SN.
    Atheroscler Suppl; 2017 Nov 17; 30():187-192. PubMed ID: 29096836
    [Abstract] [Full Text] [Related]

  • 19. Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern.
    von Dryander M, Fischer S, Passauer J, Müller G, Bornstein SR, Julius U.
    Atheroscler Suppl; 2013 Jan 17; 14(1):39-44. PubMed ID: 23357139
    [Abstract] [Full Text] [Related]

  • 20. Detailed description of the cardiovascular situation in patients who have started lipoprotein apheresis treatment.
    Schampera S, Fischer S, Weiss N, Julius U.
    Atheroscler Suppl; 2015 May 17; 18():209-14. PubMed ID: 25936328
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.